Literature DB >> 30341570

Progranulin associates with hexosaminidase A and ameliorates GM2 ganglioside accumulation and lysosomal storage in Tay-Sachs disease.

Yuehong Chen1,2, Jinlong Jian1, Aubryanna Hettinghouse1, Xueheng Zhao3, Kenneth D R Setchell3, Ying Sun3, Chuan-Ju Liu4,5.   

Abstract

Tay-Sachs disease (TSD) is a lethal lysosomal storage disease (LSD) caused by mutations in the HexA gene, which can lead to deficiency of β-hexosaminidase A (HexA) activity and consequent accumulation of its substrate, GM2 ganglioside. Recent reports that progranulin (PGRN) functions as a chaperone of lysosomal enzymes and its deficiency is associated with LSDs, including Gaucher disease and neuronal ceroid lipofuscinosis, prompted us to screen the effects of recombinant PGRN on lysosomal storage in fibroblasts from 11 patients affected by various LSDs, which led to the isolation of TSD in which PGRN demonstrated the best effects in reducing lysosomal storage. Subsequent in vivo studies revealed significant GM2 accumulation and the existence of typical TSD cells containing zebra bodies in both aged and ovalbumin-challenged adult PGRN-deficient mice. In addition, HexA, but not HexB, was aggregated in PGRN-deficient cells. Furthermore, recombinant PGRN significantly reduced GM2 accumulation and lysosomal storage in these animal models. Mechanistic studies indicated that PGRN bound to HexA through granulins G and E domain and increased the enzymatic activity and lysosomal delivery of HexA. More importantly, Pcgin, an engineered PGRN derivative bearing the granulin E domain, also effectively bound to HexA and reduced the GM2 accumulation. Collectively, these studies not only provide new insights into the pathogenesis of TSD but may also have implications for developing PGRN-based therapy for this life-threatening disorder. KEY MESSAGES: GM2 accumulation and the existence of typical TSD cells containing zebra bodies are detected in both aged and ovalbumin-challenged adult PGRN deficient mice. Recombinant PGRN significantly reduces GM2 accumulation and lysosomal storage both in vivo and in vitro, which works through increasing the expression and lysosomal delivery of HexA. Pcgin, an engineered PGRN derivative bearing the granulin E domain, also effectively binds to to HexA and reduces GM2 accumulation.

Entities:  

Keywords:  Hexosaminidase A; Lysosome storage disease; Pcgin; Progranulin; Tay-Sachs disease

Mesh:

Substances:

Year:  2018        PMID: 30341570      PMCID: PMC6240367          DOI: 10.1007/s00109-018-1703-0

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  56 in total

Review 1.  Tay-Sachs disease.

Authors:  Jose Americo Fernandes Filho; Barbara E Shapiro
Journal:  Arch Neurol       Date:  2004-09

Review 2.  Progranulin: a growth factor, a novel TNFR ligand and a drug target.

Authors:  Chuan-ju Liu; Xavier Bosch
Journal:  Pharmacol Ther       Date:  2011-10-08       Impact factor: 12.310

3.  Hexosaminidase assays.

Authors:  Michaela Wendeler; Konrad Sandhoff
Journal:  Glycoconj J       Date:  2009-11       Impact factor: 2.916

4.  Membrane lipids regulate ganglioside GM2 catabolism and GM2 activator protein activity.

Authors:  Susi Anheuser; Bernadette Breiden; Günter Schwarzmann; Konrad Sandhoff
Journal:  J Lipid Res       Date:  2015-07-14       Impact factor: 5.922

5.  Granulin epithelin precursor: a bone morphogenic protein 2-inducible growth factor that activates Erk1/2 signaling and JunB transcription factor in chondrogenesis.

Authors:  Jian Q Feng; Feng-Jin Guo; Bai-Chun Jiang; Yan Zhang; Sally Frenkel; Da-Wei Wang; Wei Tang; Yixia Xie; Chuan-Ju Liu
Journal:  FASEB J       Date:  2010-02-02       Impact factor: 5.191

6.  The lysosomal trafficking of sphingolipid activator proteins (SAPs) is mediated by sortilin.

Authors:  Stephane Lefrancois; Jibin Zeng; A Jacob Hassan; Maryssa Canuel; Carlos R Morales
Journal:  EMBO J       Date:  2003-12-15       Impact factor: 11.598

Review 7.  Secondary lipid accumulation in lysosomal disease.

Authors:  Steven U Walkley; Marie T Vanier
Journal:  Biochim Biophys Acta       Date:  2008-12-09

8.  Association Between Progranulin and Gaucher Disease.

Authors:  Jinlong Jian; Shuai Zhao; Qing-Yun Tian; Helen Liu; Yunpeng Zhao; Wen-Chi Chen; Gabriele Grunig; Paola A Torres; Betty C Wang; Bai Zeng; Gregory Pastores; Wei Tang; Ying Sun; Gregory A Grabowski; Max Xiangtian Kong; Guilin Wang; Ying Chen; Fengxia Liang; Herman S Overkleeft; Rachel Saunders-Pullman; Gerald L Chan; Chuan-Ju Liu
Journal:  EBioMedicine       Date:  2016-08-04       Impact factor: 8.143

9.  Progranulin functions as a cathepsin D chaperone to stimulate axonal outgrowth in vivo.

Authors:  Sander Beel; Matthieu Moisse; Markus Damme; Louis De Muynck; Wim Robberecht; Ludo Van Den Bosch; Paul Saftig; Philip Van Damme
Journal:  Hum Mol Genet       Date:  2017-08-01       Impact factor: 6.150

10.  Lipidomic and Transcriptomic Basis of Lysosomal Dysfunction in Progranulin Deficiency.

Authors:  Bret M Evers; Carlos Rodriguez-Navas; Rachel J Tesla; Janine Prange-Kiel; Catherine R Wasser; Kyoung Shin Yoo; Jeffrey McDonald; Basar Cenik; Thomas A Ravenscroft; Florian Plattner; Rosa Rademakers; Gang Yu; Charles L White; Joachim Herz
Journal:  Cell Rep       Date:  2017-09-12       Impact factor: 9.423

View more
  20 in total

Review 1.  Progranulin: A conductor of receptors orchestra, a chaperone of lysosomal enzymes and a therapeutic target for multiple diseases.

Authors:  Yazhou Cui; Aubryanna Hettinghouse; Chuan-Ju Liu
Journal:  Cytokine Growth Factor Rev       Date:  2019-01-30       Impact factor: 7.638

2.  Progranulin associates with Rab2 and is involved in autophagosome-lysosome fusion in Gaucher disease.

Authors:  Xiangli Zhao; Rossella Liberti; Jinlong Jian; Wenyu Fu; Aubryanna Hettinghouse; Ying Sun; Chuan-Ju Liu
Journal:  J Mol Med (Berl)       Date:  2021-08-27       Impact factor: 4.599

3.  Lysosomal Dysfunction and Other Pathomechanisms in FTLD: Evidence from Progranulin Genetics and Biology.

Authors:  Xiaolai Zhou; Thomas Kukar; Rosa Rademakers
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Jessica Root; Paola Merino; Austin Nuckols; Michelle Johnson; Thomas Kukar
Journal:  Neurobiol Dis       Date:  2021-03-31       Impact factor: 7.046

Review 5.  Precision Medicine for Lysosomal Disorders.

Authors:  Filippo Pinto E Vairo; Diana Rojas Málaga; Francyne Kubaski; Carolina Fischinger Moura de Souza; Fabiano de Oliveira Poswar; Guilherme Baldo; Roberto Giugliani
Journal:  Biomolecules       Date:  2020-07-26

6.  Impaired β-glucocerebrosidase activity and processing in frontotemporal dementia due to progranulin mutations.

Authors:  Andrew E Arrant; Jonathan R Roth; Nicholas R Boyle; Shreya N Kashyap; Madelyn Q Hoffmann; Charles F Murchison; Eliana Marisa Ramos; Alissa L Nana; Salvatore Spina; Lea T Grinberg; Bruce L Miller; William W Seeley; Erik D Roberson
Journal:  Acta Neuropathol Commun       Date:  2019-12-23       Impact factor: 7.801

7.  Assessment of cellular cobalamin metabolism in Gaucher disease.

Authors:  Suelen Porto Basgalupp; Marina Siebert; Charles Ferreira; Sidney Behringer; Ute Spiekerkoetter; Luciana Hannibal; Ida Vanessa Doederlein Schwartz
Journal:  BMC Med Genet       Date:  2020-01-13       Impact factor: 2.103

8.  Progranulin deficiency confers resistance to autoimmune encephalomyelitis in mice.

Authors:  Katja Schmitz; Annett Wilken-Schmitz; Verica Vasic; Robert Brunkhorst; Mirko Schmidt; Irmgard Tegeder
Journal:  Cell Mol Immunol       Date:  2019-08-29       Impact factor: 11.530

9.  Chemical and genetic rescue of in vivo progranulin-deficient lysosomal and autophagic defects.

Authors:  James J Doyle; Claudia Maios; Céline Vrancx; Sarah Duhaime; Babykumari Chitramuthu; Hugh P J Bennett; Andrew Bateman; J Alex Parker
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-22       Impact factor: 11.205

Review 10.  GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies.

Authors:  Andrés Felipe Leal; Eliana Benincore-Flórez; Daniela Solano-Galarza; Rafael Guillermo Garzón Jaramillo; Olga Yaneth Echeverri-Peña; Diego A Suarez; Carlos Javier Alméciga-Díaz; Angela Johana Espejo-Mojica
Journal:  Int J Mol Sci       Date:  2020-08-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.